Antibiotic use is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many cancer types (Golay and Andrea, 2020). Specifically, antibodies against the cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have shown activity against melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck cancer and other solid tumors (Golay and Andrea, 2020).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Maria Tsikala-Vafea, Neel Belani, Kendra Vieira, Hina Khan, Dimitrios Farmakiotis Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | Infectious Diseases | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer